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CASE LETTERSFig 1. Disseminated HSV infection in a patient treated
with ruxolitinib. Subcutaneous edema of the face, bifrontal
scalp ulcerations, and hemorrhagic crusting of the
conjunctival, nasal, and oral mucosae.
Fig 2. Disseminated HSV infection in a patient treated
with ruxolitinib. Necrotizing inflammation with numerous
foci of necrosis in the dermis, confluent epidermal necro-
sis, and fibrinopurulent exudate. Arrow indicates viral
inclusion within a keratinocyte. Hematoxylin-eosin stain;
340.Reactivation of herpes simplex virus infection
in a patient undergoing ruxolitinib treatment
To the Editor: Ruxolitinib (Jakafi), a selective JAK-1
and -2 inhibitor, is the first agent approved by the
Food and Drug Administration for myelofibrosis.1
Previously noted side effects include anemia, throm-
bocytopenia, and neutropenia. It is also known that
ruxolitinib can predispose to serious infections with
varicella zoster virus (VZV).
A 67-year-old African American man was started
on ruxolitinib for treatment of myelodysplastic syn-
drome at an outside hospital; he had not previously
received any other immunosuppressants. Four days
after starting ruxolitinib, swelling, blisters, and pain
of the oral mucosa developed, followed by involve-
ment of the conjunctival, nasal, and genital mucosae.
Treatment at the outside hospital consisted of
intravenous antibiotics for presumed angioedema
with bacterial superinfection and methylpredniso-
lone for possible Stevens-Johnson syndrome. His
condition continued to deteriorate, but because
there was no dermatology service available at the
outside hospital, a biopsy was not performed. One
month later, he presented to us with diffuse erosions,
ulcerations, and hemorrhagic crusting of the
conjunctival, nasal, oral, and genital mucosae
(Fig 1). He was admitted.
Magnetic resonance imaging of the face and orbits
showed extensive subcutaneous edema with both
enhancing and nonenhancing foci, suggestive of
tissue necrosis and pus. A left cheek punch biopsy
specimen showed necrotizing inflammation with
numerous foci of necrosis in the dermis, confluent
epidermal necrosis, fibrinopurulent exudate, and
scattered viral inclusions characteristic of herpes
simplex virus (HSV) in both hair follicles and
epidermis (Fig 2). Although a diagnosis of Stevens-
Johnson syndrome was not favored, it could not be
ruled out. Subsequent viral cultures of the lip were
positive for HSV-1, confirming the diagnosis of peri-
orificial HSV. The patient was started on acyclovir
720 mg intravenously every 8 hours; his condition
notably and rapidly improved. Within 3 weeks, most
of the skin and mucosae had reepithelialized.
Unfortunately, the extensive conjunctival involve-
ment led to permanent vision loss in both eyes.
HSV reactivation is often seen in immunocompro-
mised patients, such as those with organ transplan-
tation, corticosteroid use, or chemotherapy.2 Lesions
typically appear on the lips, posterior pharynx, oralJ AM ACAD DERMATOL
Open access under CC BY-NC-ND license.mucosa, and perioral skin.3 Furthermore, HSV can
disseminate in immunocompromised patients and
present with visceral involvement, such as HSV
hepatitis.4,5 This may be due to impaired T-cell and
macrophage immunity.5 Reactivated HSV often pre-
sents with nonspecific findings such as fever, leuko-
penia, and elevated aminotransferases. DefinitiveMARCH 2014 e59
Fig 1. Psoriasis vulgaris. Erythematosquamous lesions on
both lower extremities.
Fig 2. Psoriasis vulgaris. Regression of psoriatic lesions
after therapy.
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e60 Lettersdiagnosis can be made with biopsy of mucocuta-
neous lesions, polymerase chain reaction, or direct
antigen assay. Serum serologies and radiographic
findings are typically noncontributory.5
Prompt diagnosis and treatment of HSV reactiva-
tion is paramount because disseminated HSV can
lead to rapid multisystem organ failure and death.
HSV prophylaxis might be considered for patients
starting ruxolitinib therapy, especially in those with a
history of infection with human immunodeficiency
virus. This case underscores the possibility of this
devastating complication from use of this drug.
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Management of psoriasis vulgaris and multiple
sclerosis with fumaric acid
To the Editor: Psoriasis vulgaris has not only been
associated with several comorbidities like metabolic
syndrome and cardiovascular disease, but also with
neurologic disorders like multiple sclerosis (MS).1
New-onset psoriatic lesions and exacerbations have
been described after treatment with biologics for
MS, mainly interferon-beta (INF-) as well as with
other biologics such as natalizumab.2 INF- is the
first-line treatment for clinically isolated syndromewith the high risk for MS development or for
relapsing-remitting multiple sclerosis (RR-MS).
Fumaric acids have been a well-established therapy
for psoriasis vulgaris, mainly in Germany under the
trade name Fumadermea mixture of dimethyl
fumarate (DMF) and 3 salts of ethyl hydrogen
fumarate, with DMF considered to be the active
ingredient. In recent years, DMF BG-12 was also
investigated for the treatment of MS. The results of
phase 2 and 3 trials showed successfully reduced
relapse rates and time of disability progression in
patients with MS.3,4
We report a case of a 26-year-old woman in
whom optic neuritis developed. Cerebrospinal
fluid contained 9 oligoclonal bands and multifocal
hemispheral inflammatory lesions typical of MS
were seen on magnetic resonance imagining
(MRI) of the brain. The diagnosis was clinically
isolated syndrome with a high risk for MS devel-
opment. She was initially treated with systemic
corticosteroids and 2 months later INF- treatment
was started. Within half a year, an inflammatory
reaction appeared at the site of injection, which
developed into psoriasiform plaque with gradual
progression to generalized psoriatic lesions (Fig 1).
